Exact Sciences Corporation (EXAS)
| Previous close | 51.00 |
| Open | 50.70 |
| Bid | 53.44 x 600 |
| Ask | 56.22 x 100 |
| Day's range | 50.70 - 54.79 |
| 52-week range | 50.09 - 100.77 |
| Volume | |
| Avg. volume | 2,827,816 |
| Market cap | 9.874B |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
MADISON, Wis., May 21, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy’s (defendant) motion to dismiss a patent infringement lawsuit filed by Exact Sciences (plaintiff) in the United States District Court for the District of Delaware. This ruling paves the way for Exact Sciences to seek relief for Geneoscopy’s future infringement and false advertising.
- Business Wire
Exact Sciences Announces First-Quarter 2024 Results
MADISON, Wis., May 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million for the first quarter ended March 31, 2024, compared to $602 million for the same period of 2023.
- Business Wire
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024
MADISON, Wis., May 07, 2024--Exact Sciences to present strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week® 2024
